Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

-expressing, metastatic colorectal cancer is based on progression-free survival. Currently no data are available that demonstrate increased survival with Vectibix.

As seen in previous analyses of these data, the Vectibix group showed a statistically significant improvement in progression-free survival versus those who received BSC alone yielding a 46 percent decrease in the relative progression rate. The mean progression-free survival was 96 versus 60 days.

A blinded central review showed that 10 percent of patients in the Vectibix group had an objective response, while no patients in the BSC group demonstrated an objective response. Median time to response was 7.9 weeks and median duration of response was 17 weeks.

In the BSC group 174 (75 percent) patients received Vectibix under the crossover protocol. In those patients that crossed over, the objective response rate was 10 percent. The median time to crossover was 7.0 (6.6, 7.3) weeks. The median follow-up after crossover was 27 (4-69) weeks.

In the primary analysis of overall survival, there was no significant difference between the groups. The median follow-up time was 72 weeks for all patients.

A broadly-based clinical development program designed to examine the utility of Vectibix in the first- and second-line treatment of metastatic colorectal cancer, as well as head and neck cancer is ongoing.

Important Product Safety Information

As described below, the Vectibix Prescribing Information includes warning language:

Dermatologic toxicities, related to Vectibix blockade of EGF binding and subsequent inhibition of EGFr-mediated signaling pathways, were reported in 89 percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. The clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Sev
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:4/17/2015)... Steven Rash , the CEO of Algae International Group, ... Seed & Oil Company, presented the Company,s latest developments ... York City.  Mr. Rash,s presentation featured the Company,s Product ... Company has recently announced the Dube Hemp Energy ... the EpiVape , and Hempster Clothing .  ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kh5kqg/the_corporate ) ... Corporate Reputation of Pharma - The Patient Perspective ... to their offering. The Corporate Reputation ... its fourth edition. This report contains the latest ... annual Corporate Reputation report, the author surveys a ...
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, Inc. ... TWi Pharmaceuticals USA , has obtained ... United States.  It has been in close contact with ... expects to have its own label specialty generic products ... the U.S. pharma market. According to IMS ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... Data from 1,237 Facilities Demonstrates,Public Health ... States,Across Healthcare Facility Units, SAN JOSE, ... The,Association for Professionals in Infection Control ... from a nationwide study of,1,237 U.S. ...
... Is Commonly Seen In,Insulin Therapy , CHICAGO, June ... a new study that further demonstrated the safety ... Patients with Type 2 diabetes were able ... improvements in blood,sugar, comparable to dosing adjusted by ...
Cached Medicine Technology:Largest National U.S. Healthcare Facility MRSA Study Reveals,Infection Rates Eight Times Greater Than Previous Estimates 2Largest National U.S. Healthcare Facility MRSA Study Reveals,Infection Rates Eight Times Greater Than Previous Estimates 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5
(Date:4/18/2015)... (PRWEB) April 18, 2015 "I ... decided to create a healthful juice that contained ... from Rosedale, Md. "It increases my energy, improves ... body." , He developed Tapp's Juice to contain ... helps to prevent physical and mental fatigue. It ...
(Date:4/18/2015)... 18, 2015 Review of Ophthalmology magazine ... ‘Strategies for Success’ program for cataract surgeons attending the ... San Diego, where eye surgeon Jeffrey L. Martin, MD ... event. Dr. Martin is the Managing Partner of North ... chose Dr. Martin to lead this year’s discussion on ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog ... quotes . , Clients can review important auto ... online environment provides important advantages for clients who need ... who do not have coverage for their vehicles can ... day or hour. Many agencies offer important discounts and ...
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog post ... auto insurance prices . , Drivers who live ... may have to pay more for auto insurance plans ... can also offer protection against vehicle theft. , ... on a single website: http://lowcostcarinsuranceprice.com/ . Drivers ...
(Date:4/18/2015)... Lower-auto-insurance.com has released a new blog ... insurance quotes . , Drivers can find accurate ... A professional insurance brokerage website can help drivers compare ... simple, convenient way. The whole process is designed to ... Comparing online car insurance quotes is advantageous because it ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2
... less likely than non-Hispanic whites to call 9-1-1 and be ... in medical treatment delays according to a new study ... ., For the study, researchers used data from the Brain ... hospital arrival time and use of ambulance or emergency medical ...
... with a coalition of 20 international sites in five ... who have had optical coherence tomography (OCT) of the ... researchers hope will give doctors a better means to ... and sudden cardiac death. When a vulnerable ...
... say , THURSDAY, March 25 (HealthDay News) -- New research ... cancer may actually improve their survival odds, a notion contrary ... finding is significant, given that the death rate from breast ... pregnancy until later in life, the study authors said. , ...
... compared to about three-quarters of whites, Hispanics, CDC says ... the health-boosting powers of breast-feeding aren,t reaching black American ... a new study from the U.S. Centers for Disease ... that while more than 80 percent of Hispanic mothers ...
... how tumors escape the body,s natural immune surveillance has recently ... Switzerland. The study shows how tumors can create a tolerant ... key features of lymph nodes. The discovery, published in ... 25, 2010, underscores the role of the lymphatic system in ...
... ... to Raise Awareness About Malaria Prevention Aboard an Eco-Friendly Bus , ... Atlanta, GA (Vocus) March 25, 2010 -- The United ... in Africa — announced today the launch of its Nothing But Nets Buzz Tour. The ...
Cached Medicine News:Health News:Mexican Americans less likely than whites to call 9-1-1 for stroke 2Health News:Mexican Americans less likely than whites to call 9-1-1 for stroke 3Health News:Mass. General Hospital to create registry for coronary optical coherence tomography 2Health News:Pregnancy May Protect Breast Cancer Survivors 2Health News:Pregnancy May Protect Breast Cancer Survivors 3Health News:Black Women Least Likely to Breast-Feed in U.S. 2Health News:Black Women Least Likely to Breast-Feed in U.S. 3Health News:Tumors hide out from the immune system by mimicking lymph nodes 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 3
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 30 nm 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: